Connect your AI

Denali Therapeutics Inc. DNLI Earnings yield

Earnings yield at other companies

Eli LillyLLY

3.1%+1.6pp

Regeneron PharmaceuticalsREGN

5.4%-1.1pp

Ultragenyx PharmaceuticalRARE

-29.6%+144pp

Viking TherapeuticsVKTX

-12.6%-31.7pp

uniQureQURE

-20.4%-6.5pp

BiogenBIIB

5.3%-2.1pp

Other financials

Income statement

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

Market cap$3.93B+54.2%

Profitability

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Calculated from Denali Therapeutics Inc.’s reported figures.

net income/market cap=-16.7%

Based on trailing twelve months.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Denali Therapeutics Inc.'s earnings yield?: Denali Therapeutics Inc. (DNLI) reported earnings yield of -16.7% in Q1 2026.
How has Denali Therapeutics Inc.'s earnings yield changed year-over-year?: Denali Therapeutics Inc.'s earnings yield increased by 27.4% year-over-year, from -23% to -16.7%.
What is the long-term trend for Denali Therapeutics Inc.'s earnings yield?: Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s earnings yield has grown at a 95.5% compound annual growth rate (CAGR), from 0.7% to -19.9%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.